Oct 21
Current report
8-K
Events of Oct 17
Delisting notice or listing transfer, Regulation FD disclosure
FNCHQ · Finch Therapeutics Group, Inc.
$10.35
At close · Sep 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2024
Substantial doubt about the company's ability to continue as a going concern.
“due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2024
Market Cap
$16.62M
Shares
1.61M
Volume · Sep 23
5800
Avg daily vol (3M)
2195
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.35
Open$10.15
Day$10.05–10.50
52W close$6.21–14.56
Avg vol 30d2K
Short int374 · 0.0% of shares · 1.0d
Short vol94%
Last earningsMay 16, 2022
DataMar 2021–Sep 2026
Filing10-Q · Aug 13
Latest documents
2024
Aug 13
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $0
Net loss $4.83M
Diluted EPS -$3.01
Aug 12
Current report
8-K
Events of Aug 9
Other events
May 24
Current report
8-K
Events of May 23
Delisting notice or listing transfer
May 17
Current report
8-K
Events of May 14
Delisting notice or listing transfer
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$14.17M
Trailing 12 months
Revenue growth YoY
-87.6%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$25.12M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
-15.2%
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 28.2 · fear
Equity put/call 0.89
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+9%
above
RSI (14)
58
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+2%
trailing
6-month return
−23%
trailing
YTD return
−23%
this year
Relative strength
−40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-92% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of shares out · ▼ -2.6% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Fundamentals
Revenue growth
−88%
Y/Y
EPS growth
+35%
Y/Y
Free cash flow
$-31.5M
Balance sheet
$56.0M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
2.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
58
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-92% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of shares out · ▼ -2.6% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $6
Now $10 · 50%
Range high $15
vs 200-day avg -10%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FNCHQ
this stock
Finch Therapeutics Group, Inc.
|
$16.62M | -23.3% | -87.6% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$138.71B | +20.7% | +46.2% | 35.2 | 1.7% |
|
MRNA
Moderna, Inc.
|
$96.40B | +762.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$93.82B | +17.2% | +20.8% | 20.1 | 2.1% |
|
CSLLY
Csl Ltd
|
$67.11B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FNCHQ | +1.5% | +2.5% | -22.8% | +1.5% | -23.3% |
| SPY | +1.8% | +0.3% | +17.2% | +0.1% | +12.6% |
| vs SPY | -0.4% | +2.2% | -39.9% | +1.4% | -35.9% |